Shots:
- The EC has approved Sanofi‘s Teizeild (Tzield outside the EU) to delay the onset of stage 3 type 1 diabetes (T1D) in adult & pediatric pts (≥8yrs.) with stage 2 T1D; regulatory review is ongoing in the other regions
- Approval was based on the P-II (TN-10) trial assessing Teizeild (QD, n=44) vs PBO (n=32) for 14 days in 76 T1D pts, where Teizeild delayed stage 3 onset by a median of ~2yrs. vs PBO & kept 57% vs 28% of pts in stage 2
- Additionally, Sanofi is pausing its Teizeild application for recently diagnosed stage 3 T1D & is evaluating next steps with the EMA
Ref: Globenewswire | Image: Sanofi | Press Release
Related News: Earendil Labs and Sanofi Forge ~$2.56B Deal to Advance Bispecific Antibodies for Autoimmune Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
